Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer

Fig. 4

Conjugated RBGO1 antibody co-localises with LAMP1 indicating lysosomal trafficking and accumulation following internalization. Following inhibition of lysosomal action, HEC1A endometrial cancer cells were incubated with control medium or medium containing RBGO1 antibody conjugated to FITC (50 μg/ml) for 6 or 10 h. After fixing and permeablisation, cells were stained with a rabbit anti-LAMP1 antibody to detect the lysosomal compartment. Images were acquired on a Zeiss LSM 710 confocal microscope and analyzed using the Zen 2012 image analysis software (a). The quantity of internalized antibody was determined using Image J software as a function of cell area (G). Histogram data are expressed as mean (SD) from 3 independent experiments (b). Data were analyzed by ANOVA and Dunnett’s multiple comparison test. Pearson’s correlation coefficient (PCC) and Manders col-localisation coefficient were performed to assess co-localisation. Values differ from 6 h, *p < 0.05

Back to article page